AAM Rejects FDA’s Updated Biosimilar Naming Policy

Drug Industry Daily
A A
The Association for Accessible Medicines (AAM) and its Biosimilars Council is urging the FDA to scrap its proposed suffix-based naming policy for biological products because it would act as “a barrier to biosimilars access.”

To View This Article:

Login

Subscribe To Drug Industry Daily